LIVE POLIO IRUS VACCINES

More documents

Recommendations

Info

lmllliiimlll1llrrmmIiiiiiiiiiiiiii,,,,, ... ,.................................., miiiiiiiiriiiiim irrm-rmiiir-r EIGHTH SESSION THURSDAY, 9 JUNE 1960, 2:00 P.M. Chairman DR. CHARLES H. STUART-HARRIS Professor of Medicine University of Sheffield Sheffield, England TOPIC III. EFFICACY. (continuation) (B) FIELD EVIDENCE (DISCUSSION) Presentation of Papers by: Dr. V. Skovránek Dr. F. Przesmycki (DISCUSSION) Dr. N. Oker-Blom Dr. J. J. Alcocer Dr. Oscar Vargas-Méndez Dr. J. M. Quirce (DISCUSSION) Dr. V. M. Zhdanov 503
Page 1 and 2:
LIVE POLIO IRUS VACCINES Papers Pre
Page 3 and 4:
SECOND INTERNATIONAL CONFERENCE ON
Page 5:
Preface The accumulation of informa
Page 8 and 9:
Page Discussion .......... .......
Page 10 and 11:
Page 6. Vaccination of Full-Term In
Page 12 and 13:
Page 23. Vaccination against Poliom
Page 14 and 15:
Dr. Ghislain COURTOIS Director, Pri
Page 16 and 17:
Dr. Edith PETTE Institute for the R
Page 18:
imimmmmmñimmimmm-ñmñmñrmimmimmm
Page 21 and 22:
4 Introductory Remarks 4 Introducto
Page 23 and 24:
6 General Considerations immunity a
Page 25 and 26:
8 General Considerations from accep
Page 27 and 28:
10 General Considerations 10 Genera
Page 29 and 30:
_nTlmmlllllTlllllllnT/I1T~lllmlimll
Page 31 and 32:
14 Safety-Laboratory Evidence of At
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
- 26 Safety-Laboratory Evidence of
Page 45 and 46:
DISCUSSION CHAIRMAN ANDERSON: There
Page 47 and 48:
30 Discussion CHAIRMAN ANDERSON: Th
Page 49 and 50:
32 TABLE 1. Safety-Laboratory Evide
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
40 Discussion Of the 22 monkeys inf
Page 59 and 60:
Page 61 and 62:
DISCUSSION CHAIRMAN ANDERSON: Thank
Page 63 and 64:
46 Discussion a paralytic case. Thi
Page 65 and 66:
48 Discussion + - + + I + - I + + 1
Page 67 and 68:
50 Discussion sages of neurovirulen
Page 70 and 71:
UUYaYLlrmUIIIIIIYYIi1IYllllliTI11II
Page 72 and 73:
Application of Genetic Markers to D
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Discussion 67 TABLE 1. INCIDENCE OF
Page 86 and 87:
Experimental Studies on Animals wit
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
6. DETECTION OF A "NON-DETECTABLE"
Page 98 and 99:
Detection of a "Non-Detectable" Sim
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Discussion 87 Dr. Koprowski's state
Page 106 and 107:
Discussion 89 recognize its effects
Page 108 and 109:
Laboratory Investigations of Attenu
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Discussion 99 In the case of Table
Page 118 and 119:
8. BEHAVIOR OF COLD MUTANTS OF POLI
Page 120 and 121:
Behavior of Cold Mutants of Poliovi
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
DISCUSSION CHAIRMAN BURNET: Thank y
Page 128:
IULUUmmiillaYIIiiiiIllnllTrTnTnTm T
Page 131 and 132:
114 Safety-Field Evidence of Safety
Page 133 and 134:
Page 135 and 136:
118 S afety-Field Evidence of S af
Page 137 and 138:
Page 139 and 140:
122 Discussion 122 Discussion~~~~~~
Page 141 and 142:
10. LABORATORY INVESTIGATIONS OF TH
Page 143 and 144:
126 VIRUS 1 MAhONEY Safety-Field Ev
Page 145 and 146:
128 Safety-Field Evidence óf Safet
Page 147 and 148:
Page 149 and 150:
DISCUSSION CHAIRMAN ZHDANOV: This p
Page 151 and 152:
11. EPIDEMIOLOGICAL AND VIROLOGICAL
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
12. SPREAD OF A VACCINE STRAIN OF P
Page 163 and 164:
Page 165 and 166:
148 Saf ety-Field Evidence of Saf e
Page 167 and 168:
Page 169 and 170:
152 Saf ety-Field Evidence of Safet
Page 171 and 172:
Page 173 and 174:
DISCUSSION CHAIRMAN ZHDANOV: The pa
Page 175 and 176:
158 Discussion 158 Díscussion~~~~~
Page 177 and 178:
160 Discussion specimens. We were u
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
. . . 168 Safety-Field Evidence of
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
14. THE CAPACITY OF LIVE ATTENUATED
Page 193 and 194:
176 Saf ety-Field Evidence of Saf e
Page 195 and 196:
... ____ v __ _"_ _. ___.__ __ .,_.
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 204 and 205:
"""lliiiiirmlilrrmiiiiiiiii iiiii,,
Page 206 and 207:
Field, Laboratory Experiences With
Page 208 and 209:
16. STUDIES ON LIVE POLIOVIRUS VACC
Page 210 and 211:
Studies on Live Poliovirus Vaccine
Page 212 and 213:
; _ o - -01 1 0 h 4.cccM oe u, Co F
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Da. HORSTMANN: If I may answer for
Page 222 and 223:
Discussion 205 Discussion 205 tried
Page 224 and 225:
NOTE: The Spanish translation of th
Page 226 and 227:
Vaccination of Pregnant Women and Y
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Development and Persistence of Poli
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Virologic, Serologic Investigations
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
_ _ _ _ _ _ _ _ Virologic, Serologi
Page 282 and 283:
Page 284 and 285:
cARE NUC:4I Discussion 267 CUAw # J
Page 286 and 287:
Discussion 269 in the investigation
Page 288 and 289:
Virological Findings, Antibody Resp
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
4. ROUTINE IMMUNIZATION WITH ATTENU
Page 296 and 297:
Routine Immunization With Attenuate
Page 298 and 299:
Page 300:
Page 304 and 305:
mmrriiiiiiiiiiiinniiiiiiiriiimmmmmn
Page 306 and 307:
Experimental Infectionwith CHATAtte
Page 308 and 309:
Experimental Infection with CHATAtt
Page 310 and 311:
Experimental Infection with CHATAtt
Page 312 and 313:
Vaccination of Full-Term Infants wi
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Response of Newborn Infants to Vacc
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Susceptibility of Newborn Infants t
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
9. IMMUNIZATION OF NEWBORN INFANTS
Page 334 and 335:
Immunization of Newborn Infants wit
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Discussion 323 vaccinated siblings
Page 342 and 343:
Discussion 325 Discussion 325 ance
Page 344 and 345:
transplacental antibodies, or antib
Page 346 and 347:
Discussion 329 Discussion 329 born
Page 348 and 349:
Recent Experience with Lederle Triv
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
11. FURTHER EXPERIENCES WITH ORAL P
Page 360 and 361:
Further Experiences with Oral Polio
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370:
Page 374 and 375:
_1111_11111111111111llllIllllllllll
Page 376 and 377:
Minnesota Studies with Oral Poliomy
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
13. USE OF ATTENUATED LIVE POLIOVIR
Page 384 and 385:
Use of Attenuated Live Poliovirus V
Page 386 and 387:
Use of Attenuated Live Poliovirus V
Page 388 and 389:
DISCUSSION CHAIRMAN LÉPINE: The tw
Page 390 and 391:
Discussion 373 -~~~~~~ics o 7 domin
Page 392 and 393:
Discussion 375 -~ ~~~~isuso 7 DR. C
Page 394 and 395:
i 14. EFFECTS OF RAPID MASS IMMUNIZ
Page 396 and 397:
Live Poliovirus Immunization-Condit
Page 398 and 399:
Page 400 and 401:
Page 402 and 403:
Page 404 and 405:
Use of Sabin's Live Poliovirus Vacc
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
- Use of Sabin's Live Poliovirus Va
Page 412 and 413:
Page 414 and 415:
TABLE 14. Use of Sabin's Live Polio
Page 416 and 417:
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
Page 426 and 427:
Page 428 and 429:
Discussion 411 DR. ANDERSON: My que
Page 430 and 431:
llllllmlllllmlllllI 1111111111··
Page 432 and 433:
Course of Mass Immunization in USSR
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
, _ _ Course of Mass Immunization i
Page 442 and 443:
Page 444 and 445:
Page 446 and 447:
DISCUSSION CHAIRMAN LÉPINE: Thank
Page 448 and 449:
Discussion 431 DR. STUART-HARRIS: I
Page 450:
_llmrr//lnlllllllllllllllllllilllll
Page 453 and 454:
436 Efficacy-Field Evidence TABLE 1
Page 455 and 456:
438 Efficacy-Field Evidence Adminis
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
444 Effcaey-Field Evidence 44 Efiay
Page 463 and 464:
446 Efficacy-Field Evidence 446 Eff
Page 465 and 466:
448 Efficacy-Field Evidence 448 lEf
Page 467 and 468:
450 Efficacy-Field Evidence m Co 0
Page 469 and 470: 452 Efficacy-Field Evidence ] ~~ ~
Page 471 and 472: 454 Efficacy-Field Evidence It is n
Page 473 and 474: 456 Efficacy-Field Evidence M.G. C
Page 475 and 476: 458 Discussion 458 Discussion~~~~~~
Page 477 and 478: 460 460 Discussion Discussion~~~~~~
Page 479 and 480: 462 Discussion one was sponsored by
Page 481 and 482: 464 Discussion 464 Discussion~~~~~~
Page 484 and 485: Vaccination with CHAT Strain Type 1
Page 492 and 493: Live Virus Vaccine Studies in South
Page 498 and 499: Discussion 481 the ages of the five
Page 500 and 501: Immunological and Epidemiological E
Page 518: Immunological and Epidemiological E
Page 523 and 524: 506 Discussi on hausted the morbidi
Page 525 and 526: 508 Efficacy-Field Evidence TABLE 1
Page 527 and 528: 510 Efficacy-Field Evidence b 'r3 `
Page 529 and 530: 512 ol o c,- 4 3- 0 7 Efficacy-Fiel
Page 531 and 532: 514 Efficacy-Field Evidence b, U *
Page 533 and 534: 516 Efficacy-Field Evidence o e 0 1
Page 535 and 536: 518 Efficacy-Field Evidence in the
Page 537 and 538: 520 Efficacy-Field Evidence thing w
Page 539 and 540: 23. VACCINATION AGAINST POLIOMYELIT
Page 545 and 546: 528 Efficacy-Field Evidence MAP 2.
Page 549 and 550: DISCUSSION CHAIRMAN STUART-HARRIS:
Page 551 and 552: 534 Efficacy-Field Evidence a still
Page 553 and 554: 536 Efficacy-Field Evidence frigera
Page 555 and 556: 538 TABLE 3. Efficacy-Field Evidenc
Page 557 and 558: 540 Efficacy-Field Evidence sented
Page 561 and 562: 544 Efficacy-Field Evidence Antibod
Page 563 and 564: 546 Efficacy-Field Evidence 250t 20
Page 567 and 568: 550 Efficacy-Field Evidence FIGURE
Page 569 and 570:
552 Efficacy-Field Evidence u o o
Page 571 and 572:
-Y 554 Efficacy-Field Evidence TABL
Page 573 and 574:
556 -- Efficacy-Field Evidence 0
Page 575 and 576:
c 558 Efficacy-Field Evidence o z o
Page 577 and 578:
560 Efficacy-Field Evidence Clayton
Page 579 and 580:
562 Efficacy-Field Evidence 2. Triv
Page 581 and 582:
564 Efficacy-Field Evidence and by
Page 583 and 584:
566 Efficacy-Field Evidence establi
Page 585 and 586:
568 Efficacy-Field Evidence Costa R
Page 587 and 588:
570 Efficacy-Fi eld Evidence Two su
Page 589 and 590:
572 Efficacy-Field Evidence o0 u p
Page 591 and 592:
DISCUSSION CHAIRMAN STUART-HARRIS:
Page 593 and 594:
27. LARGE-SCALE PRACTICAL TRIALS AN
Page 595 and 596:
578 Efficacy-Field Evidence some of
Page 597 and 598:
580 Efficacy-Field Evidence vaccine
Page 599 and 600:
582 Efficacy-Field Evidence more th
Page 601 and 602:
584 Efficacy-Field Evidence medical
Page 603 and 604:
586 Efficacy-Field Evidence immuniz
Page 605 and 606:
588 Efficacy-Field Evidence nationa
Page 608 and 609:
DISCUSSION CHAIRMAN VARGAS-MÉNDEZ:
Page 610 and 611:
Discussion 593 -~~~~~isuso 9 a stoo
Page 612 and 613:
Discussion 595 If the chain of tran
Page 614 and 615:
dence of immunization within a few
Page 616 and 617:
Discussion 599 the people in a few
Page 618 and 619:
Summary of the Conference 601 prese
Page 620:
The occurrence of poliomyelitis in
Page 624 and 625:
INDEX Abad Gómez, Héctor, 369 Abo
Page 626 and 627:
Index 609 Attack rates-continued hi
Page 628 and 629:
Index 611 Chromatography purificati
Page 630 and 631:
Index 613 Dosage-continued statisti
Page 632 and 633:
Index 615 Field trials-continued Le
Page 634 and 635:
Index 617 Human tissue-culture syst
Page 636 and 637:
Index 619 Intestinal tract-continue
Page 638 and 639:
Index 621 Markush, R. E., paper 435
Page 640 and 641:
Index 623 Newborns-continued degree
Page 642 and 643:
Index 625 Poliomyelitis, paralytic-
Page 644 and 645:
Index 627 Reversion dangers of, 485
Page 646 and 647:
Index 629 Spread-continued in the c
Page 648 and 649:
Index 631 Vaccination-continued rep
Page 650 and 651:
Index 633 Vaccine, Attenuated, Triv
show all

LIVE POLIO IRUS VACCINES

Create successful ePaper yourself

Delete template?

Save as template?